RESUMEN
Background: The outbreak of acute respiratory syndrome with novel coronavirus 2019 (COVID-19) in December 2019 in Wuhan, China, caused a worldwide outbreak of the disease. To treat the disease, some drugs were identified and introduced that did not show a significant effect on the recovery of the disease. Due to the need to manage inpatient beds, this study was conducted to evaluate the effectiveness of Remdesivir in the treatment of outpatients with moderate to severe COVID-19. Method(s): The present study was a retrospective cohort with a convenience sampling method. It was conducted by referring to the records of COVID-19 patients who were referred to the respiratory clinic of Shahid Beheshti Hospital as outpatients in the period from April to August 2021. Result(s): This study was conducted on 263 COVID-19 patients with a mean age of 51.16+/-14.39 years from 19 and 90 years old. Data were collected through a researcher-made checklist and analyzed using SPSS 20. Kolmogorov-Smirnov test, paired t-test, and Mc Nemar's test were used to evaluate the data. The significance level was considered at the level of 0.05. Conclusion(s): Findings revealed that no clear correlation was found between hospitalization and death rate compared to other patients. In our study, the risk factors for severe COVID-19 did not affect the rate of hospitalization or death of patients.Copyright © 2023 Bentham Science Publishers.
RESUMEN
Coronavirus disease 2019 (COVID-19) is a worldwide public health problem that has attracted much attention due to its clinical findin gs. Measurement of IgG and IgM antibodies is of great importance for researchers and it will help t o develop a new diagnostic and therapeutic method in clinical care. In this cross-sectional study, we aim to measure th e IgG and IgM antibody levels in 401 suspected COVID-19 volunteers. We also measure the time duration for the appearance of IgG and IgM antibodies from the onset of symptoms to sa mpling time. Of 401 participants enrolled in the study, 255 (63.59%) were healthy, 79 (19.70%) were a carrier, 59 (14.71%) were cured and 8 (1.99%) were borderline. Of 142 subjects diagnosed with COVID-19, 41 (28.87%) presented with gastrointestin al (GI) symptoms, 83 (58.45%) had no GI symptoms, and 18 (12.68%) were asymptomatic. According to our findings, the measurement of IgG a nd IgM antibodies will provide the tool for the diagnosis of COVID-19 and significantly boo st research into novel diagnostic and therapeutic approaches.
RESUMEN
Background: Seeking new specific and effective drugs against Coronavirus Diseases-2019 (COVID-19) is of great importance. This study describes the efficacy of remdesivir with supportive care alone in the treatment of critically sick adult and child COVID-19 patients. Method(s): This study was a one-blind placebo-controlled, randomized clinical trial in adults (aged>=18 years) and children (aged<=12 years) in Iran. Patients were included if they had positive PCR test for SARS-CoV-2 infection, O2 saturation <=88%, and compatible symptoms. All participants received standard care following national treatment guidelines. The treatment group received remdesivir (200 mg IV on day 1 and followed by 100 mg in single daily infusions). The control group received standard care and an identical volume of placebo infusions (Water for injection) for 5 days. For pediatric patients, the intervention group received remdesivir (5mg/kg on the first day and then 5.2 mg/kg on days 2 to 5). Discharge from the hospital within 10 days of first treatment is considered as the primary endpoint of the study. Admission in the intensive care unit (ICU) is considered as original secondary endpoint of the study. Result(s): 141 patients were enrolled and randomly assigned to two group (adults;54 patients in the intervention group vs. 52 patients in the control group, and children;17 patients in the intervention group vs. 18 patients in the control group). The mean time from the first symptoms until the referral to the hospital in adult patients was 5.61 +/- 2.67 day and 4.80+/-1.48 day for intervention and control groups, respectively. The mean time from the first symptoms until death was reported to be significant and was longer for intervention group than the control group (24.83 +/- 11.25 vs. 10.50 +/- 2.42 day;p value=0. 012). For children who received remdesivir, the mean time between admission until death was reported to be significant, as the finding high-lighted a longer time duration for the intervention group (13.55 +/- 0.72 vs. 10.66 +/- 0.57 day;p value=0. Mechanicalanical ventilation was used in 17 patients (100%) and 18 patients (100%) in the intervention and control groups, respectively (p value=0.853). Conclusion(s): Among patients with critical COVID-19, those randomized to a 5-day treatment of remdesivir did have a statistically significant difference in clinical status compared with the control group of both adults and children. Clinical Trial Registration Number: This study is registered in the Iranian Registry of Clinical Trial (No. IRCT 20200405046953N1). Copyright © 2023 Bentham Science Publishers.
RESUMEN
Introduction: The COVID-19 disease is caused by SARS-coronavirus-2. The corona virus mainly causes damage to the pulmonary epithelial cells of lung, as well as other organs such as the hearts and immune system by interaction of its spike protein with host ACE2 receptor. There is currently no specific treatment for coronary disease. Mesenchymal stem cell may be a potential treatment for refractory pulmonary illnesses. Methods: To conduct this review study, the databases of PubMed, Scopus, clinicaltrials.gov, world health organization international clinical trials registry platform and european union clinical trials register were searched using the keywords of COVID-19 and mesenchymal stem cells in 2020. Then, by exact examining of the title, the summary and full text of articles, repeat studies and cases that lacked inclusion criteria were excluded. In these studies, the pathological symptoms of coronary patients as well as the characteristics, origin, and potential mechanisms of stem cells in coronary artery disease and MSC-based clinical trials were investigated. Results: Mesenchymal stem cells have significant effects on the treatment of COVID-19 disease due to their unique properties such as immune system regulation and tissue regeneration capabilities. Also, in this way, several studies have been licensed to enter the clinical phase and are under investigation. Conclusion: Although treatment of corona disease using stem cells is a very promising method, but the limitations of this therapeutic approach must be considered. So, there is an urgent need for large-scale investigations to confirm the safety and efficacy profile of these therapies and rigorous resolution on several fronts, including MSC fate after infusion, homing capability and MSC resistance to the disease microenvironment. © 2021, Shahroud University of Medical Sciences. All rights reserved.
RESUMEN
Introduction: New Coronavirus disease 2019 (COVID-19) has caused serious health problems worldwide. The disease first started in Wuhan, China, and then resulted in thousands of deaths throughout the world. Case Presentation: According to data from involved patients, children and neonates include a small proportion of patients with COVID-19. However, in some cases, hospitalization and even death still may occur. In this case report, we described mortality associated with COVID-19 in two pediatrics from Qom city, Iran. One of them presented with severe symptoms that needed high-flow ventilation and admission to the ICU. Conclusions: The findings of this report confirm that COVID-19 may cause death in pediatrics, like in adults. Timely diagnosis, precise evaluation of clinical symptoms, and effective treatment of COVID-19-infected children can play an important role in reducing mortality rates.
RESUMEN
Introduction: Considering the increasing number of patients referred to gastroenterology clinics, we report a suspected case of coronavirus disease 2019 (COVID-19) with only gastrointestinal (GI) presentation in Qom, Iran. Case Presentation: A 74-year-old man with epigastric pain, diarrhea and vomiting for one week was treated, based on the routine abdominal treatment protocol. Since all GI symptoms were resistant to therapy, we decided to perform laboratory assays for a more accurate diagnosis of the disease. Considering the persistence of abdominal pain and nausea, abdominal and pelvic computed tomography (CT) scans, as well as endoscopy and colonoscopy, were performed. After performing the chest CT scan, we noticed the involvement of the lungs. The patient did not have any respiratory symptoms, and at the time of his hospitalization, the COVID-19 epidemic had been reported in Iran. With the progression of the disease, he started to experience mild fever (38°C). Using a specific COVID-19 kit, he was diagnosed with COVID-19 after precise evaluations. However, without any medications, all of his symptoms subsided after 2-3 weeks. Conclusions: It is important for all physicians to know that some pure GI symptoms, which are resistant to therapy, may be the only symptoms in suspected COVID-19 patients. Timely diagnosis and isolation of these patients can guarantee population to avoid the spread of this highly contagious infection.